(MedPage Today) — Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose schizophrenia was being treated with the second-generation antipsychotics clozapine or olanzapine.
The…
Source link : https://www.medpagetoday.com/psychiatry/schizophrenia/118814
Author :
Publish date : 2025-12-03 20:50:00
Copyright for syndicated content belongs to the linked Source.
